• 2026-10-26 09:52:44

The Food and Drug Administration of the Philippines (PFDA) has circulated a revised draft Circular proposing updated regulatory guidelines for Medical Device Software (MDSW), including AI-enabled MDSW. The draft outlines software qualification criteria, risk-based classification, product authorization pathways, and technical documentation requirements for initial and renewal applications. It also introduces AI-specific requirements covering clinical validation, cybersecurity, risk management, and post-market monitoring. The proposed guidelines aim to strengthen the safety and performance of MDSW throughout its lifecycle. The Circular remains in draft form and is not yet effective.

• 2026-09-21 02:52:44

In Japan, Software as a Medical Device (SaMD) within certification criteria is reviewed and certified by Registered Certification Bodies (RCBs). Any product that exceeds the definition of its generic name, established certification standards, or the range of equivalence to predicate devices is subject to be reviewed by PMDA for approval.
Recently, it has been discovered that several cases in which the main and additional functions of SaMD products exceeded the certification scope. PMDA published this notice to prevent the recurrence of similar inappropriate certifications by standardizing and clarifying the requirements for describing software functions (Reference 1).

• 2026-08-25 04:50:05

Indonesia's medical device regulatory framework places increasing emphasis on demonstrating compliance with applicable healthcare standards through appropriate testing and validation. Manufacturers and applicants should ensure that the required test results, validation documents, and supporting certifications are available as part of the product registration and compliance process. Recent requirements highlighted for in vitro diagnostic products (IVDs) include specific provisions for performance testing, instrument connectivity, and software validation.

• 2025-09-24 07:20:49

The FDA has issued draft guidance on marketing submissions for AI-enabled device software functions (AI-DSFs), with a focus on using a predetermined change control plan (PCCP). A PCCP allows manufacturers to plan and manage software changes in a predictable and controlled way, making regulatory review smoother and device performance more reliable.

• 2025-02-20 10:32:57

The FDA has released a draft on lifecycle management and marketing submission recommendations for devices that include AI-enabled software functions. This draft incorporates the Total Product Life Cycle (TPLC) approach and guiding principles for Good Machine Learning Practice (GMLP).

• 2024-09-17 05:57:50

Australia's TGA has issued two new guidance on software-based medical devices. Sponsors must comply with the new classification rules with the transition period ending by November 1, 2024. Additionally, the TGA clarified which software products are subject to regulation, providing clear guidelines for industry.

• 2023-11-20 02:19:57

This guidance provides clarifications on which specific regulatory considerations apply when the hardware or hardware component are classified as a medical device or an accessory to a medical device.

• 2023-09-27 07:05:52

The Japanese MHLW has issued Q&A on Software Cybersecurity that was newly added to the Essential Principle

• 2023-07-21 02:14:29

The US FDA recently issued an updated guidance aimed at providing comprehensive information on the recommended documentation for premarket submissions. The purpose of this guidance is to assist the FDA in evaluating the safety and effectiveness of device software functions.

• 2023-05-24 07:21:35

The Japanese MHLW has issued a complimentary notice to explain further about cybersecurity of the Essential Principles Requirements.